Absent 99mTc-MIBI Uptake in the Thyroid Gland during Early Phase of Parathyroid Scintigraphy in Patients with Primary and Secondary Hyperparathyroidism
DOI:
https://doi.org/10.3889/oamjms.2018.118Keywords:
Parathyroid scintigraphy, Diminished thyroid MIBI uptake, Primary hyperparathyroidism, Chronic renal failureAbstract
BACKGROUND: Thyroid uptake of technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) during parathyroid scintigraphy can be affected by various conditions.
AIM: To evaluate the frequency of absent 99mTc-MIBI uptake by the thyroid gland in the early phase of dual-phase parathyroid scintigraphy.
METHODS: The early planar images of dual phase Tc99m MIBI parathyroid scintigraphy from 217 patients performed between 2014 and 2017 were retrospectively analysed. Patients were divided into two groups. The first group included 147 patients with primary hyperparathyroidism and the second group included 70 patients with chronic renal failure. Patient records, laboratory and ultrasonographic data were analysed in all patients. Descriptive statistic was used for data analysis.
RESULTS: Out of all patients in the first group, 18 patients (12.24%) showed absent thyroid uptake. Thyroidectomy was performed in 44.4% of these patients, and the rest of them had some thyroid disease. Only one patient had no thyroid or another chronic disease. In the second group, 8 patients (11.42%) presented with absent thyroid uptake of MIBI. Among them, 5 patients had no history of thyroid disease and had been on hemodialysis programme, and 3 patients had hypothyroidism.
CONCLUSION: Absent 99mTc-MIBI uptake in the thyroid during the early phase of parathyroid scintigraphy is most frequently related to thyroid disease. A small proportion of patients with chronic renal failure can present with absent 99mTc-MIBI uptake in the thyroid as well. The mechanism for this alteration is still unclear and needs further investigation.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Eslamy HK, Ziessman H a. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. Radiographics. 2008; 28:1461–76. https://doi.org/10.1148/rg.285075055 PMid:18794320
Taïeb D, Ure-a-Torres P, Zanotti-Fregonara P, Rubello D, Ferretti A, Henter I, et al. Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. Clin Nucl Med. 2013; 38(8):630–5. https://doi.org/10.1097/RLU.0b013e31829af5bf PMid:23751837 PMCid:PMC4300197
Coakley AJ, Kettle AG, Wells CP, O'Doherty MJ, Collins RE. 99Tcm sestamibi--a new agent for parathyroid imaging. Nucl Med Commun. 1989; 10(11):791–4. https://doi.org/10.1097/00006231-198911000-00003 PMid:2532313
Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med. 1992; 33(10):1801–7. PMid:1328564
Özgen Kiratli P, Ceylan E, Naldöken S, Beylergil V. Impaired Tc-99m MIBI uptake in the thyroid and parathyroid glands during early phase imaging in hemodialysis patients. Rev Esp Med Nucl. 2004; 23(5):347–51. https://doi.org/10.1016/S0212-6982(04)72315-0
Koca G, Atilgan HI, Baskin A, Demirel K, Korkmaz M. Non-visualized Thyroid Gland by Tc-99m MIBI Scan with Normal Thyroid Scan. Nucl Med Mol Imaging (2010). 2013; 47(3):216–7. https://doi.org/10.1007/s13139-013-0198-4 PMid:24900113 PMCid:PMC4035197
Piccardo A, Puntoni M, Treglia G, Foppiani L, Bertagna F, Paparo F, et al. Thyroid nodules with indeterminate cytology: Prospective comparison between 18F-FDG-PET/CT, multiparametric neck ultrasonography, 99mTc-MIBI scintigraphy and histology. Eur J Endocrinol. 2016; 174(5):693–703. https://doi.org/10.1530/EJE-15-1199 PMid:26966173
Kresnik E, Gallowitsch HJ, Mikosch P, Gomez I, Lind P. Technetium-99m-MIBI scintigraphy of thyroid nodules in an endemic goiter area. J Nucl Med. 1997; 38(1):62–5. PMid:8998152
Santos AO, Zantut-Wittmann DE, Nogueira RO, Etchebehere ECSC, Lima MCL, Tambascia MA, et al. 99mTc-sestamibi thyroid uptake in euthyroid individuals and in patients with autoimmune thyroid disease. Eur J Nucl Med Mol Imaging. 2005; 32(6):702–7. https://doi.org/10.1007/s00259-004-1728-1 PMid:15703932
Gómez-RamÃrez J, Posada M, RodrÃguez A, Bravo JM, DomÃnguez L, MartÃn-Pérez ME, et al. [Thyroid suppression in patients with primary hyperparathyroidism: does it improve the pre-surgical scintigraphy localisation?]. CirugÃa espa-ola. 2011; 89(9):595–8. https://doi.org/10.1016/j.ciresp.2011.06.003 PMid:21867995
Wang J, Zhang R. Evaluation of (99m)Tc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol. 2017; 90(1071):20160836. https://doi.org/10.1259/bjr.20160836 PMid:28106465 PMCid:PMC5601526
Saeki M, Kurose K, Tohkin M, Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol. 2008; 76(4):531–42. https://doi.org/10.1016/j.bcp.2008.05.030 PMid:18602086
Bhatnagar A, Vezza PR, Bryan JA, Atkins FB ZH. Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability. J Nucl Med. 1998; 39(9):1617–20. PMid:9744355
Kandeel A, Hawary M, Ebaid H. Technetium-99m Sestamibi Scintigraphy Pattern in Patients with Secondary Hyperparathyroidism. Arab J Nephrol Transplant. 2009; 2(2):16–20.
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0